发布求助
文献互助 智能选刊 最新文献

Current Opinion in Pharmacology最新文献

筛选
英文 中文
Adenosine signaling as target in cardiovascular pharmacology 腺苷信号传导作为心血管药理学的靶点。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-08-01 DOI: 10.1016/j.coph.2023.102393
Luca Antonioli , Matteo Fornai , Carolina Pellegrini , Pál Pacher , György Haskó
{"title":"Adenosine signaling as target in cardiovascular pharmacology","authors":"Luca Antonioli ,&nbsp;Matteo Fornai ,&nbsp;Carolina Pellegrini ,&nbsp;Pál Pacher ,&nbsp;György Haskó","doi":"10.1016/j.coph.2023.102393","DOIUrl":"10.1016/j.coph.2023.102393","url":null,"abstract":"<div><p><span><span>Increasing evidence demonstrated the relevance of adenosine system in the onset and development of cardiovascular diseases, such as hypertension, myocardial infarct, ischemia, hypertension, heart failure, and atherosclerosis. In this regard, intense research efforts are being focused on the characterization of the pathophysiological significance of adenosine, acting at its </span>membrane receptors named A</span><sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub><span> receptors, in cardiovascular diseases. The present review article provides an integrated and comprehensive overview about current clinical and pre-clinical evidence about the role of adenosine in the pathophysiology of cardiovascular diseases. Particular attention has been focused on current scientific evidence about the pharmacological ligands acting on adenosine pathway as useful tools to manage cardiovascular diseases.</span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"71 ","pages":"Article 102393"},"PeriodicalIF":4.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NMR applications to GPCR recognition by peptide ligands NMR在肽配体GPCR识别中的应用
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102366
Kazem Asadollahi , Daniel J. Scott , Paul R. Gooley
{"title":"NMR applications to GPCR recognition by peptide ligands","authors":"Kazem Asadollahi ,&nbsp;Daniel J. Scott ,&nbsp;Paul R. Gooley","doi":"10.1016/j.coph.2023.102366","DOIUrl":"10.1016/j.coph.2023.102366","url":null,"abstract":"<div><p>Peptides form the largest group of ligands that modulate the activity of more than 120 different GPCRs. Among which linear disordered peptide ligands usually undergo significant conformational changes upon binding that is essential for receptor recognition and activation. Conformational selection and induced fit are the extreme mechanisms of coupled folding and binding that can be distinguished by analysis of binding pathways by methods that include NMR. However, the large size of GPCRs in membrane-mimetic environments limits NMR applications. In this review, we highlight advances in the field that can be adopted to address coupled folding and binding of peptide ligands to their cognate receptors.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102366"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9603082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Purinergic signaling pathway in severe COVID-19 重症新冠肺炎的嘌呤能信号通路
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102379
Lourdes Arruvito, Inés Sananez, Vanesa Seery, Constanza Russo, Jorge Geffner
{"title":"Purinergic signaling pathway in severe COVID-19","authors":"Lourdes Arruvito,&nbsp;Inés Sananez,&nbsp;Vanesa Seery,&nbsp;Constanza Russo,&nbsp;Jorge Geffner","doi":"10.1016/j.coph.2023.102379","DOIUrl":"10.1016/j.coph.2023.102379","url":null,"abstract":"<div><p>Substantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation is usually associated to the release of ATP from different cell types, starting a cascade of events through the activation of a set of different purinergic receptors. This review summarizes the evidence showing the involvement of the purinergic system in the inflammatory condition that characterizes severe COVID-19.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102379"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9605008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma 晚期肝细胞癌个体化一线系统治疗的思考
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102365
Frederik Peeters, Jeroen Dekervel
{"title":"Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma","authors":"Frederik Peeters,&nbsp;Jeroen Dekervel","doi":"10.1016/j.coph.2023.102365","DOIUrl":"10.1016/j.coph.2023.102365","url":null,"abstract":"<div><p><span><span>Primary liver cancer is the third most common cause of cancer-related death worldwide and hepatocellular carcinoma (HCC) accounts for approximately 80%–90% of all primary liver malignancies. Until 2007, there was no effective treatment option available for patients diagnosed with advanced HCC, whereas today, both multireceptor </span>tyrosine kinase inhibitors as well as </span>immunotherapy combinations have entered clinical practice.</p><p>The choice between the different options is a tailor-made decision to match the efficacy and safety data of the clinical trials with the specific patient and disease profile. This review provides clinical stepstones to make an individualized decision for every patient with its specific tumor and liver characteristics in mind.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102365"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9977040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Highlighting vulnerabilities in the alternative lengthening of telomeres pathway 强调端粒替代延长途径的脆弱性
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102380
Lisa M. Carson, Rachel L. Flynn
{"title":"Highlighting vulnerabilities in the alternative lengthening of telomeres pathway","authors":"Lisa M. Carson,&nbsp;Rachel L. Flynn","doi":"10.1016/j.coph.2023.102380","DOIUrl":"10.1016/j.coph.2023.102380","url":null,"abstract":"<div><p><span>The alternative lengthening of telomeres (ALT) pathway is a telomere elongation mechanism found in a small but often aggressive subset of cancers. Dependent on break-induced replication, telomere extension in ALT-positive cells relies on a baseline level of </span>DNA replication stress to initiate elongation events. This results in an elevated level of DNA damage and presents a possible vulnerability to be exploited in the development of ALT-targeted cancer therapies. Currently, there are no treatment options that target the ALT mechanism or that are specific for ALT-positive tumors. Here, we review recent developments and promising directions in the development of ALT-targeted therapeutics, many of which involve tipping the balance towards inhibition or exacerbation of ALT activity to selectively target these cells.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102380"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9978578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Extracellular adenosine signaling in bone health and disease 细胞外腺苷信号在骨骼健康和疾病中的作用
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102378
Hunter Newman , Shyni Varghese
{"title":"Extracellular adenosine signaling in bone health and disease","authors":"Hunter Newman ,&nbsp;Shyni Varghese","doi":"10.1016/j.coph.2023.102378","DOIUrl":"10.1016/j.coph.2023.102378","url":null,"abstract":"<div><p>Purinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor<span> signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis. Extracellular adenosine is mainly produced by ectonucleotidases, and alterations in the function of these enzymes or compromised adenosine generation can result in bone disorders, such as osteoporosis and impaired fracture healing. This mini review discusses the key role played by adenosine in bone health and how its alterations contribute to bone diseases, as well as potential therapeutic applications of exogenous adenosine to combat bone diseases like osteoporosis and injury.</span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102378"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9596720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting DNA damage repair precision medicine strategies in cancer 癌症靶向DNA损伤修复精准医疗策略
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102381
Juliette Brownlie , Sanat Kulkarni , Mashael Algethami , Jennie N. Jeyapalan , Nigel P. Mongan , Emad A. Rakha , Srinivasan Madhusudan
{"title":"Targeting DNA damage repair precision medicine strategies in cancer","authors":"Juliette Brownlie ,&nbsp;Sanat Kulkarni ,&nbsp;Mashael Algethami ,&nbsp;Jennie N. Jeyapalan ,&nbsp;Nigel P. Mongan ,&nbsp;Emad A. Rakha ,&nbsp;Srinivasan Madhusudan","doi":"10.1016/j.coph.2023.102381","DOIUrl":"10.1016/j.coph.2023.102381","url":null,"abstract":"<div><p>DNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The development and clinical use of PARP inhibitors has transformed lives for many patients with <em>BRCA</em> germline deficient breast and ovarian cancer as well as platinum sensitive epithelial ovarian cancers. However, lessons learnt from the clinical use of PARP inhibitors also confirm that not all patients respond either due to intrinsic or acquired resistance. Therefore, the search for additional synthetic lethality approaches is an active area of translational and clinical research. Here, we review the current clinical state of PARP inhibitors and other evolving DNA repair targets including ATM, ATR, WEE1 inhibitors and others in cancer.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102381"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9660135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeting the altered duodenal microenvironment in functional dyspepsia 靶向改变的十二指肠微环境治疗功能性消化不良
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102363
Matthias Ceulemans , Lucas Wauters , Tim Vanuytsel
{"title":"Targeting the altered duodenal microenvironment in functional dyspepsia","authors":"Matthias Ceulemans ,&nbsp;Lucas Wauters ,&nbsp;Tim Vanuytsel","doi":"10.1016/j.coph.2023.102363","DOIUrl":"10.1016/j.coph.2023.102363","url":null,"abstract":"<div><p><span><span>Duodenal micro-inflammation and microbial dysregulation are increasingly recognized to play an important role in functional dyspepsia (FD) </span>pathophysiology<span>, previously regarded as a purely functional disorder. With current therapeutic options contested through insufficient efficacy or unfavorable adverse effects<span> profiles, novel treatments directed to duodenal alterations could result in superior symptom control in at least a subset of patients. Indeed, recent advances in FD research provided evidence for anti-inflammatory therapies to relieve gastroduodenal symptoms by reducing duodenal eosinophils or mast cells. In addition, restoring microbial homeostasis by probiotics<span> proved to be successful in FD. As the exact mechanisms by which these novel pharmacological approaches result in clinical benefit often remain to be elucidated, future research should focus on how immune activation and dysbiosis translate into typical FD </span></span></span></span>symptomatology.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102363"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9959781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries 肝细胞癌患者肝动脉灌注化疗在西方国家的适用性
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-06-01 DOI: 10.1016/j.coph.2023.102362
MinKe He , ShuYue Liu , ZhiCheng Lai , ZeFeng Du , QiJiong Li , Li Xu , Anna Kan , JianXian Shen , Ming Shi
{"title":"Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries","authors":"MinKe He ,&nbsp;ShuYue Liu ,&nbsp;ZhiCheng Lai ,&nbsp;ZeFeng Du ,&nbsp;QiJiong Li ,&nbsp;Li Xu ,&nbsp;Anna Kan ,&nbsp;JianXian Shen ,&nbsp;Ming Shi","doi":"10.1016/j.coph.2023.102362","DOIUrl":"10.1016/j.coph.2023.102362","url":null,"abstract":"<div><p>Hepatic arterial infusion chemotherapy with oxaliplatin<span>, 5-fluorouracil, and leucovorin<span><span><span> (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China. Different from hepatocellular carcinoma in China, hepatocellular carcinoma in Western countries is caused by hepatitis C and </span>alcoholic liver disease, and is often diagnosed at an early stage, when the tumor is small or the </span>thrombus is not serious. Although there are no reports of FOLFOX-HAIC efficacy for hepatocellular carcinoma in Western countries, FOLFOX-HAIC can be used in patients with large tumors (&gt; 5 cm) (or T3 by TNM stage), and rich blood supply.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"70 ","pages":"Article 102362"},"PeriodicalIF":4.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9605237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug development for the treatment of RyR1-related skeletal muscle diseases 治疗RyR1相关骨骼肌疾病的药物开发
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2023-04-01 DOI: 10.1016/j.coph.2023.102356
Takashi Murayama , Nagomi Kurebayashi , Ryosuke Ishida , Hiroyuki Kagechika
{"title":"Drug development for the treatment of RyR1-related skeletal muscle diseases","authors":"Takashi Murayama ,&nbsp;Nagomi Kurebayashi ,&nbsp;Ryosuke Ishida ,&nbsp;Hiroyuki Kagechika","doi":"10.1016/j.coph.2023.102356","DOIUrl":"10.1016/j.coph.2023.102356","url":null,"abstract":"<div><p>Type 1 ryanodine receptor (RyR1) is an intracellular Ca<sup>2+</sup><span> release channel on the sarcoplasmic reticulum<span> of skeletal muscle, and it plays a central role in excitation–contraction (E-C) coupling. Mutations in RyR1 are implicated in various muscle diseases<span> including malignant hyperthermia<span>, central core disease, and myopathies. Currently, no specific treatment exists for most of these diseases. Recently, high-throughput screening (HTS) assays have been developed for identifying potential candidates for treating RyR-related muscle diseases. Currently, two different methods, namely a FRET-based assay and an endoplasmic reticulum Ca</span></span></span></span><sup>2+</sup>-based assay, are available. These assays identified several compounds as novel RyR1 inhibitors. In addition, the development of a reconstituted platform permitted HTS assays for E-C coupling modulators. In this review, we will focus on recent progress in HTS assays and discuss future perspectives of these promising approaches.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"69 ","pages":"Article 102356"},"PeriodicalIF":4.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9497217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信